S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

$6.90
+0.88 (+14.63 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$6.33
Now: $6.90
$8.49
50-Day Range
$6.01
MA: $6.76
$7.54
52-Week Range
$2.96
Now: $6.90
$18.15
Volume305,959 shs
Average Volume53,448 shs
Market Capitalization$34.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.97 million
Book Value($5.91) per share

Profitability

Net Income$-16,380,000.00

Miscellaneous

Employees124
Market Cap$34.24 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.


Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) issued its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.45. The biopharmaceutical company earned $17.35 million during the quarter, compared to analysts' expectations of $14.50 million. View Alimera Sciences' Earnings History.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Alimera Sciences.

What price target have analysts set for ALIM?

3 brokers have issued 12-month target prices for Alimera Sciences' stock. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' stock price to reach $30.00 in the next year. This suggests a possible upside of 335.1% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

What is the consensus analysts' recommendation for Alimera Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

Has Alimera Sciences been receiving favorable news coverage?

News articles about ALIM stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alimera Sciences earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Alimera Sciences.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 22,700 shares, a decline of 28.8% from the January 30th total of 31,900 shares. Based on an average daily volume of 64,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.6% of the shares of the stock are short sold. View Alimera Sciences' Current Options Chain.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
  • Dr. Kenneth Green, Consultant (Age 61)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 55)

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (4.04%), Renaissance Technologies LLC (1.52%), Royce & Associates LP (0.93%), JW Asset Management LLC (0.55%) and Geode Capital Management LLC (0.21%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.

Which institutional investors are selling Alimera Sciences stock?

ALIM stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, Royce & Associates LP, JW Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Alimera Sciences.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $6.90.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $34.24 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is http://www.alimerasciences.com/.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  639
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel